Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Alderson

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Lancet (London, England)|March 14, 2025
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trialFatoumata Diallo, Fadima C Haidara, Milagritos D Tapia, et al.
The Journal of Infection|November 28, 2021
Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative reviewMark R Alderson, Peter D Arkwright, Xilian Bai, et al.
The New England Journal of Medicine|June 2, 2021
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian ToddlersMilagritos D Tapia, Samba O Sow, Abdi Naficy, et al.
The Lancet. Infectious Diseases|August 19, 2018
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled studyWilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, et al.
The Lancet. Infectious Diseases|January 31, 2021
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trialEd Clarke, Adedapo Bashorun, Ikechukwu Adigweme, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Pathogens (Basel, Switzerland)|August 28, 2021
Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global UseBarbara Bolgiano, Eilís Moran, Nicola J Beresford, et al.
The New England Journal of Medicine|May 24, 2023
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and GambiaFadima C Haidara, Ama Umesi, Samba O Sow, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Lancet (London, England)|March 14, 2025
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trialFatoumata Diallo, Fadima C Haidara, Milagritos D Tapia, et al.
The Journal of Infection|November 28, 2021
Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative reviewMark R Alderson, Peter D Arkwright, Xilian Bai, et al.
The New England Journal of Medicine|June 2, 2021
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian ToddlersMilagritos D Tapia, Samba O Sow, Abdi Naficy, et al.
The Lancet. Infectious Diseases|August 19, 2018
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled studyWilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, et al.
The Lancet. Infectious Diseases|January 31, 2021
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trialEd Clarke, Adedapo Bashorun, Ikechukwu Adigweme, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Pathogens (Basel, Switzerland)|August 28, 2021
Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global UseBarbara Bolgiano, Eilís Moran, Nicola J Beresford, et al.
The New England Journal of Medicine|May 24, 2023
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and GambiaFadima C Haidara, Ama Umesi, Samba O Sow, et al.
Pageof 4